Email this article EFFEKTIVNOST' NEYROPROTEKTORNOY TERAPII V VOSSTANOVITEL'NOM LEChENII NEPROLIFERATIVNOY DIABETIChESKOY RETINOPATII
- Authors: Yurova O.V.1, Turova EA1, Morozova N.E.1, Rogan OA1, Nazarova G.A.1
-
Affiliations:
- Issue: Vol 10, No 6 (2011)
- Pages: 35-38
- Section: Articles
- Published:
- URL: https://journals.eco-vector.com/2078-1962/article/view/608749
- ID: 608749
Cite item
Full Text
Abstract
Purpose: The efficacy evaluation of the application of new physiotherapeutic method with neuroprotective and antioxidant agent semax in patients with nonproliferative diabetic retinopathy.
Methods: 114 patients (228 eyes) with diabetes mellitus and nonproliferative diabetic retinopathy at the age of 42 to 70 were investigated. Three groups were formed subject to the therapy. Patients in first (main) group got endonasal electrophoresis of semax. Patients in second group (of comparison) provided treatment with intranasal instillations of semax, and patients in third (control group), as the first two groups, received simultaneous hypoglycemic standard therapy and the drug Doxy-Hem.
Results: After the provided treatment in the first main group and in the second group of comparison the clinically apparent and significant positive dynamics of examined indices was fixed (of visual, perimetritic and electrophysiological indices). The most apparent and long-lasted (to 6 months) positive results were got in first group of patients.
Conclusion: The results received in present investigation allow to recommend the method of endonasal electrophoresis semax 0,1% in complex rehabilitation treatment in patients with diabetes mellitus and nonproliferative diabetic retinopathy.
Methods: 114 patients (228 eyes) with diabetes mellitus and nonproliferative diabetic retinopathy at the age of 42 to 70 were investigated. Three groups were formed subject to the therapy. Patients in first (main) group got endonasal electrophoresis of semax. Patients in second group (of comparison) provided treatment with intranasal instillations of semax, and patients in third (control group), as the first two groups, received simultaneous hypoglycemic standard therapy and the drug Doxy-Hem.
Results: After the provided treatment in the first main group and in the second group of comparison the clinically apparent and significant positive dynamics of examined indices was fixed (of visual, perimetritic and electrophysiological indices). The most apparent and long-lasted (to 6 months) positive results were got in first group of patients.
Conclusion: The results received in present investigation allow to recommend the method of endonasal electrophoresis semax 0,1% in complex rehabilitation treatment in patients with diabetes mellitus and nonproliferative diabetic retinopathy.
About the authors
Ol'ga Valentinovna Yurova
Email: docolga08@mail.ru
E A Turova
Natal'ya Evgen'evna Morozova
Email: natnkm@mail.ru
O A Rogan
Galina Aleksandrovna Nazarova
Email: irisclips@gmail.ru
References
- Ашмарин И.П., Незавибатько В.Н., Мясоедов Н.Ф. и др. Ноотропный аналог адренокортикотропина 4-10- Семакс (15-летний опыт разработки и изучения) // Журнал ВНД. - 1997. - Т. 47, № 3. - С. 420-430.
- Гаврилова Н.А. Патогенетические механизмы развития диабетической ретинопатии, диагностика ранних стадий. Прогноз и профилактика развития, дифференцированный подход к лечению. // Автореферат дисс. ... д.м.н. М., 2004.
- Захаров В.Д. Витреоретинальная микрохирургия. - М., 2003.
- Исакова З.Ж. Комплексное лечение непролиферативной диабетической ретинопатии. // Автореферат дисс. ...к.м.н. М., 2002.
- Марченко Л.Н. Нейропротекция при заболеваниях сетчатки и зрительного нерва. - Минск, 2003. - 363 с.
- Полунин Г.С., Нуриева С.М., Баяндин Д.Л. и др. Определение терапевтической эффективности нового отечественного препарата Семакс при заболеваниях зрительного нерва // Вестн. офтальмол. - 2000. - Т. 116, № 1. - С. 15-18.
- Castillo M. , Bellot J.L., Garcia-Cabanes С. et al. Effects of hypoxia on retinal pigmented epithelium cells: protection by antioxidants // Opthalmic Res. - 2002. - № 6. - P. 338 - 342.
- Smith S.C. Focus on diabetes // Insight. - 2006. - Vol. 31, № 1. - P. 21-22.
- Mattews D.R., I.M. Stratton, S.J. Aldington et al. UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related // Arch. Opthalmol. - 2004. - Vol. 122, № 11. - P. 1631-1640
Supplementary files
